President CEO, DirectorMr. Paul V. Campanelli serve as President, Chief Executive Officer, Director of the Company. Mr. Campanelli joined Endo in 2015 as the President of Par Pharmaceutical, leading Endos fully integrated U.S. Generics business, following Endos acquisition of Par Pharmaceutical. Prior to joining Endo, he had served as Chief Executive Officer of Par Pharmaceutical Companies, Inc. following the companys September 2012 acquisition by TPG. While CEO of Par, Mr. Campanelli built a strong leadership team and an industryleading generics business. Under his leadership, the company significantly increased total revenue, acquired Michiganbased JHP Pharmaceuticals, established a business office in London to serve as Pars entry point into the European generics market and completed its acquisition of an active pharmaceutical ingredients facility located in Chennai, India. Prior to the TPG acquisition, Mr. Campanelli served as Chief Operating Officer and President of Par Pharmaceutical, Inc., the companys generics division, from 2011 to 2012. Earlier in his tenure at Par, Mr. Campanelli held roles of increasing responsibility, including Senior Vice President, Business Development Licensing Executive Vice President and President of Par Pharmaceutical, Inc. and was named a Corporationrationrate Officer by Pars board of directors. He also served on the board of directors of Sky Growth Holdings Corporationrationration. Prior to joining Par, Mr. Campanelli served as Vice President, Business Development at Dr. Reddys Laboratories Ltd. where he was employed from 19922001
Age: 53 CEO Since 2016Campanelli earned his BS degree from Springfield College.